Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
05:11pm, Friday, 03'rd Jun 2022
Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way. The post 6 Biotech Stocks to Buy Now Ahead o
Why Is Acadia (ACAD) Down 13.9% Since Last Earnings Report?
03:31pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Acadia (ACAD) Down 13.9% Since Last Earnings Report?
12:49pm, Friday, 03'rd Jun 2022
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
08:00am, Friday, 03'rd Jun 2022
ATLANTA--(BUSINESS WIRE)---- $ACAD #ACImmune--Alzamend Neuro to Present at 12th Annual LD Micro Invitational Investor Conference; Focuses on Progress with Clinical Trials & INDs for AL001 & AL002
Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
02:06pm, Thursday, 05'th May 2022 Zacks Investment Research
Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.
ACADIA Pharmaceuticals Inc. (ACAD) CEO Stephen Davis on Q1 2022 Results - Earnings Call Transcript
10:35pm, Wednesday, 04'th May 2022
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mark Johnson - VP, IR Stephen Davis - CEO Brendan Teehan - COO and Head, Commerc
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
10:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Acadia (ACAD) delivered earnings and revenue surprises of -42.86% and 6.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
Zymeworks Inc. (ZYME) Surges 23.2%: Is This an Indication of Further Gains?
10:36am, Monday, 02'nd May 2022 Zacks Investment Research
Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stre
Acadia: Catalysts Stacking
06:16pm, Thursday, 28'th Apr 2022
The lead drug (Nuplazid) is enjoying aggressive sales growth and thereby trumping competitors. In taking success to the next level, Acadia is expanding Nuplazid's label for schizophrenia and Alzheimer
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
04:50pm, Wednesday, 27'th Apr 2022
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis
07:49pm, Tuesday, 19'th Apr 2022 Benzinga
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain following bunionectomy, a surgical procedure that moves
Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal
04:02pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
Acadia's (ACAD) phase II study, evaluating ACP-044 for treating acute pain following bunionectomy surgery, misses the primary endpoint. Stock down.
Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal
01:33pm, Tuesday, 19'th Apr 2022
Acadia's (ACAD) phase II study, evaluating ACP-044 for treating acute pain following bunionectomy surgery, misses the primary endpoint. Stock down.
